Johnson & Johnson (US)
Best-known for babycare and Band-Aids, Johnson & Johnson has long been one of the world's biggest healthcare manufacturers, and got even bigger in 2006 with the purchase of the consumer health division of Pfizer. In fact, consumer products had until then been the group's smallest segment. The largest chunk of group revenues still comes from pharmaceuticals, including blockbusters such as Remicade, Procrit and Risperdal, and medical devices. The group flavours a highly decentralised structure with a broad portfolio of almost 200 separately branded subsidiary businesses, operating as McNeil, Janssen, Depuy and Ethicon among many others. Key brands under the group's umbrella include Tylenol, Neutrogena, Aveeno and Ortho contraceptives, as well as medical devices, surgical products and Acuevue contact lenses. Despite its size, Johnson & Johnson has endured tough trading in recent years, especially in the US, as a result of a series of manufacturing problems and product recalls that have tainted the reputations of several of its best-known consumer brands.
Which agencies handle advertising for Johnson & Johnson? Find out more from Account Assignments
Who are the competitors of Johnson & Johnson? See Pharmaceutical Sector and Personal Care Sector indexes
Latest news about Johnson & Johnson? Click here for recent headlines from Adbrands Weekly Update
Adbrands Company Profiles provide a detailed analysis of the history and current operations of leading advertisers, agencies and brands worldwide, and include a critical summary which identifies key strengths and weaknesses. Adbrands Account Assignments tracks account management for the world's leading brands and companies, including details of which advertising agency handles which accounts in which countries for major markets.
Recent stories from Adbrands Weekly Update:
Adbrands Weekly Update 7th Nov 2013: Deutsch returned to the Johnson & Johnson roster, replacing IPG stablemate McCann on the Acuevue account.
Adbrands Weekly Update 7th Nov 2013: Johnson & Johnson is to pay fines and settlements totaling $2.2bn to US regulators for off-label promotions - where medicines are prescribed for illnesses for which they have not been licensed - and kickbacks to doctors and pharmacists covering several drugs including the anti-psychotic Risperdal. It is the third largest pharmaceutical-related settlement in US history after GSK's 2012 fine of $3bn and a $2.3bn deal with Pfizer in 2009. Johnson & Johnson also agreed to submit itself to a five-year "corporate integrity" agreement, allowing the Department of Health & Social Services to scrutinise its ongoing business operations to ensure no further contravention.
Adbrands Weekly Update 31st Oct 2013: Alison Lewis, who resigned last week from her role as CMO at Coca-Cola North America, revealed that she has accepted the job of global chief marketing officer for Johnson & Johnson consumer companies, overseeing marketing for a huge range of products from Band-aid and Listerine to Neutrogena and Tylenol.
Subscribers may access the following website links:
Johnson & Johnson website
Adbrands.net. All rights reserved © Mind Advertising Ltd 1998-2013